Akt inhibitor SC66 promotes cell sensitivity to cisplatin in chemoresistant ovarian cancer cells through inhibition of COL11A1 expression
Tóm tắt
Từ khóa
Tài liệu tham khảo
Ozols, R. F. Systemic therapy for ovarian cancer: current status and new treatments. Semin. Oncol. 33 (2Suppl 6), S3–S11 (2006).
Waldmann, A., Eisemann, N. & Katalinic, A. Epidemiology of malignant cervical, corpus uteri and ovarian tumours—current data and epidemiological trends. Geburtsh Frauenheilk 73, 123–129 (2013).
Bookman, M. A. et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III trial of the gynecologic cancer intergroup. J. Clin. Oncol. 27, 1419–1425 (2009).
Nicholson, K. M. & Anderson, N. G. The protein kinase B/Akt signaling pathway in human malignancy. Cell Signal. 14, 381–395 (2002).
Xue, G. & Hemmings, B. A. PKB/Akt-dependent regulation of cell motility. J. Natl Cancer Inst. 105, 393–404 (2013).
Al-Bazz, Y. O., Underwood, J. C., Brown, B. L. & Dobson, P. R. Prognostic significance of Akt, phospho-Akt and BAD expression in primary breast cancer. Eur. J. Cancer 45, 694–704 (2009).
Robey, R. B. & Hay, N. Is Akt the “Warburg kinase”?-Akt-energy metabolism interactions and oncogenesis. Semin. Cancer Biol. 19, 25–31 (2009).
Bellacosa, A., Kumar, C. C., Di Cristofano, A. & Testa, J. R. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv. Cancer Res. 94, 29–86 (2005).
Li, J. et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943–1947 (1997).
Steck, P. A. et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15, 356–362 (1997).
Shayesteh, L. et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet. 21, 99–102 (1999).
Samuels, Y. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554 (2004).
Staal, S. P. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc. Natl Acad. Sci. USA 84, 5034–5037 (1987).
Wu, G. et al. Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res. 7, R609–R616 (2005).
Carpten, J. D. et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448, 439–444 (2007).
Parikh, C. et al. Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers. Proc. Natl Acad. Sci. USA 109, 19368–19373 (2012).
Brugge, J., Hung, M. C. & Mills, G. B. A new mutational AKTivation in the PI3K pathway. Cancer Cell 12, 104–107 (2007).
Clark, A. S., West, K., Streicher, S. & Dennis, P. A. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol. Cancer Ther. 1, 707–717 (2002).
LoPiccolo, J., Blumenthal, G. M., Bernstein, W. B. & Dennis, P. A. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist. Updat. 11, 32–50 (2007).
Wu, Y. H., Chang, T. H., Huang, Y. F., Huang, H. D. & Chou, C. Y. COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer. Oncogene 33, 3432–3440 (2014).
Wu, Y. H., Chang, T. H., Huang, Y. F., Chen, C. C. & Chou, C. Y. COL11A1 confers chemoresistance on ovarian cancer cells through the activation of Akt/c/EBPβ pathway and PDK1 stabilization. Oncotarget 6, 23748–23763 (2015).
Wu, Y. H., Huang, Y. F., Chang, T. H. & Chou, C. Y. Activation of TWIST1 by COL11A1 promotes chemoresistance and inhibits apoptosis in ovarian cancer cells by modulating NF-κB-mediated IKKβ expression. Int. J. Cancer 141, 2305–2317 (2017).
Jo, H. et al. Deactivation of Akt by small moclule inhibitor targeting pleckstrin homology domain and facilitating Akt ubiquitination. Proc. Natl Acad. Sci. USA 108, 6486–6491 (2011).
Rashmi, R. et al. AKT inhibitors promote cell death in cervical cancer through disruption of mTOR signaling and glucose uptake. PLoS ONE 9, e92948 (2014).
Cusimano, A. et al. Cytotoxic activity of the novel small molecular AKT inhibitor SC66 in hepatocellular carcinoma cells. Oncotarget 6, 1707–1722 (2015).
Vivanco, I. & Sawyers, C. L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2, 489–501 (2002).
Perez-Tenorio, G. & Stal, O., Group SSBC. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br. J. Cancer 86, 540–545 (2002).
Dai, D. L., Martinka, M. & Li, G. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J. Clin. Oncol. 23, 1473–1482 (2005).
Massarelli, E. et al. Akt activation correlates with adverse outcome in tongue cancer. Cancer 104, 2430–2436 (2005).
Yoshioka, A. et al. The activation of Akt during preoperative chemotherapy for esophageal cancer correlates with poor prognosis. Oncol. Rep. 19, 1099–1107 (2008).
Jia, W. et al. REDD1 and p-AKT over-expression may predict poor prognosis in ovarian cancer. Int. J. Clin. Exp. Pathol. 7, 5940–5949 (2014).
Huang, J. et al. Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome. Genes Chromosomes Cancer 50, 606–618 (2011).
Tanaka, Y. et al. Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer. Cancer Biol. Ther. 11, 50–57 (2011).
Woenckhaus, J. et al. Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer. Virchows Arch. 450, 387–395 (2007).
Garcia-Echeverria, C. & Sellers, W. R. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 27, 5511–5526 (2008).
Ihle, N. T. & Powis, G. Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy. Mol. Cancer Ther. 8, 1–9 (2009).
Liao, Y. & Hung, M. C. Physiological regulation of Akt activity and stability. Am. J. Transl. Res. 2, 19–42 (2010).
Lin, Y. H. et al. The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells. Naunyn Schmiedebergs Arch. Pharmacol. 388, 19–31 (2015).
Li, J., Wood, W. H. 3rd, Becker, K. G., Weeraratna, A. T. & Morin, P. J. Gene expression response to cisplatin treatment in drug-sensitive and drug-resistant ovarian cancer cells. Oncogene 26, 2860–2872 (2007).
Latifi, A. et al. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. J. Cell Biochem. 112, 2850–2864 (2011).
Zhu, X. et al. miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin. Oncogene 35, 323–332 (2016).
Wang, X. et al. Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells. Oncogene 23, 474–482 (2004).
Yang, J. et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117, 927–939 (2004).
Yang, Z. et al. Up-regulation of gastric cancer cell invasion by Twist is accompanied by N-cadherin and fibronectin expression. Biochem. Biophys. Res. Commun. 358, 925–930 (2007).
Lee, T. K. et al. Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin. Cancer Res. 12, 5369–5376 (2006).
Weiss, M. B. et al. TWIST1 is an ERK1/2 effector that promotes invasion and regulates MMP-1 expression in human melanoma cells. Cancer Res. 72, 6382–6392 (2012).
Chiu, W. T. et al. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells. Oncotarget 6, 2349–2365 (2015).
Chou, T. C. & Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27–55 (1984).